Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) Operating margin
Merck & Co., Inc.'s operating margin over the twelve months to 30 June 2026 was 10.5%, down 23.5 percentage points from fiscal 2025 (34.0%). Over the past ten years it has ranged from 4.91% (fiscal 2023) to 34.0% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers General industry median of 18.9% and above the Healthcare sector median of 0.00%.
Operating margin, annual
Annual
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | 34.0% | 2.50 |
| FY2024 | 31.5% | 26.60 |
| FY2023 | 4.91% | (25.93) |
| FY2022 | 30.8% | 3.74 |
| FY2021 | 27.1% | 13.74 |
| FY2020 | 13.4% | (6.90) |
| FY2019 | 20.3% | (0.86) |
| FY2018 | 21.1% | 4.18 |
| FY2017 | 16.9% | 3.13 |
| FY2016 | 13.8% | (5.30) |
Quarterly
| Period | Operating margin | Change (points) |
|---|---|---|
| Jun 2026 | −2.61% | 17.04 |
| Mar 2026 | −19.7% | (44.43) |
| Dec 2025 | 24.8% | (13.16) |
| Sep 2025 | 37.9% | 2.81 |
| 42 more quarters | Free account |
Against its own ten years
Low 4.91%
High 34.0%
Ten-year median
20.3%
Current reading's percentile
100
Operating margin against peers
| Company | Operating margin |
|---|---|
| NVO Novo Nordisk A/S compare | 43.4% |
| NVS Novartis AG compare | 30.2% |
| AMGN Amgen Inc. compare | 30.0% |
| JNJ Johnson & Johnson compare | 27.7% |
| ABBV AbbVie Inc. compare | 26.2% |
| AZN AstraZeneca PLC compare | 22.8% |
| PFE Pfizer Inc. compare | 21.7% |
| MRK Merck & Co., Inc. | 10.5% |
| GILD Gilead Sciences, Inc. compare | −8.20% |
| Drug Manufacturers General industry median | 18.9% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement